Sveriges mest populära poddar
New Retina Radio by Eyetube
VetenskapTeknologi

Continuous Dosing in LADDER

8 min•4 augusti 2020

The phase 2 LADDER study showed the Port Delivery System for ranibizumab was worthy of a phase 3 trial. Was the device able to deliver a continuous dose of therapy that was similar to what you’d find in monthly injection patients? Dilsher Dhoot, MD, reviews the pharmacokinetic data that researchers used to determine the rate of drug release and therapeutic benefit and previews the phase 3 ARCHWAY trial. 


This editorially independent podcast is supported with advertising.

Fler avsnitt av New Retina Radio by Eyetube

Visa alla avsnitt av New Retina Radio by Eyetube
The Fellow Eye: Episode 6
•41 min
ASRS '26: SOL-1 and TRUCKEE at 4.5 Years
•24 min
New Retina Radio Journal Club w/ VBS: Clinical Features and Outcomes of IOFB Removal
•17 min
How EYP-1901 Addresses IL-6 Drivers in Wet AMD and DME
•29 min
Barriers to Care, Patient Education, and Treatment Decisions in Geographic Atrophy
•16 min
Evolving Practice Patterns and Dosing Strategies in Geographic Atrophy
•18 min
Biomarkers, Imaging, and Early Treatment Decisions in Geographic Atrophy
•14 min
The Fellow Eye: Episode 5
•39 min
Retinal Perfusion, Sensitivity, and Function in DR
•16 min
Spotlight on UNITY® VCS: Experience Extraordinary
•30 min

New Retina Radio by Eyetube med Retina Today finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.